News
Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.
Dupilumab use in asthma linked to higher lymphoma risk, especially T/NK cell types, though overall mortality was lower, new ...
Discover a study where results suggest a statistically significant association between dupilumab and psoriasis, although the clinical impact may be limited.
The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.
[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...
Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...
Bio-Thera Solutions and SteinCares have signed a new agreement to commercialize a proposed biosimilar of dupilumab across ...
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...
10dOpinion
MedPage Today on MSN'5 Years, 10 Years at Most, I'm Going to Retire': What We Heard This Week"A lot of my friends are in their late 50s, and they're already talking about, 'OK, maybe in the next 5 years, 10 years at ...
The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that ...
Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results